NT-702 (parogrelil hydrochloride, NM-702), a novel and potent phosphodiesterase 3 inhibitor, suppress the asthmatic response in guinea pigs, with both bronchodilating and anti-inflammatory effects

European Journal of Pharmacology

Volumn 618, Issue 1-3, 2009, Pages 63-69

  Hori, Miyuki ^a   Iwama, Takehisa ^b   Asakura, Yumiko ^a   Kawanishi, Masafumi ^a   Kamon, Junji ^b   Hoshino, Akihiko ^a   Takahashi, Shuya ^a   Takahashi, Kenzo ^a   Nakaike, Shiro ^a   Tsuruzoe, Nobutomo ^b  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

^b NISSAN CHEMICAL INDUSTRIES LTD   (Japan)

Author keywords

Airway hyperresponsiveness; Guinea pig; Immediate asthmatic response; Late asthmatic response; NT 702; Phosphodiesterase 3 inhibitor

Indexed keywords

4 BROMO 6 [3 (4 CHLOROPHENYL)PROPOXY] 5 [(PYRIDINE 3 YLMETHYL)AMINO]PYRIDAZIN 3(2H) ONE; AMINOPHYLLINE; CYCLIC AMP; NT 702; PHOSPHODIESTERASE III INHIBITOR; SALBUTAMOL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BRONCHODILATING ACTIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; GUINEA PIG; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; SMOOTH MUSCLE RELAXATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIGENS; ASTHMA; BRONCHOCONSTRICTION; BRONCHODILATOR AGENTS; CELL MOVEMENT; CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; DINOPROSTONE; ENZYME INHIBITORS; GUINEA PIGS; HISTAMINE; LEUKOTRIENE D4; LUNG; MALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH; PYRIDAZINES; TRACHEA;

EID: 68949167650     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.07.005     Document Type: Article

References (42)

1. Abdullah A.K., and Khan S. Evidence-based selection of inhaled corticosteroid for treatment of chronic asthma. J. Asthma 44 (2007) 1-12
2. 2+ influx in airway smooth muscle. Am. J. Physiol. Lung. Cell. Mol. Physiol. 290 (2006) L278-L283
3. Barnes P.J. Cyclic nucleotide and phosphodiesterase and airway function. Eur. Respir. J. 8 (1995) 457-462
4. Bernareggi M.M., Belvisi M.G., Patel H., Barnes P.J., and Giembycz M.A. Anti-spasmogenic activity of isoenzyme-selective phosphodiesterase inhibitors in guinea-pig trachealis. Br. J. Pharmacol. 128 (1999) 327-336
5. Boswell-Smith V., Cazzola M., and Page C.P. Are phosphodiesterase 4 inhibitors just more theophylline?. J. Allergy. Clin. Immunol. 117 (2006) 1237-1243
6. Boswell-Smith V., Spina D., and Page C.P. Phosphodiesterase inhibitors. Br. J. Pharmacol. 147 Suppl 1 (2006) S252-257
7. Brass E.P., Anthony R., Cobb F.R., Koda I., Jiao J., and Hiatt W.R. The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J. Am. Coll. Cardiol. 48 (2006) 2539-2545
8. Chung K.F. Phosphodiesterase inhibitors in airway disease. Eur. J. Pharmacol. 533 (2006) 110-117
9. Coyle A.J., Ackerman S.J., Burch R., Proud D., and Irvin C.G. Human eosinophil-granule major basic protein and synthetic polycations induce airway hyperresponsiveness in vivo dependent on bradykinin generation. J. Clin. Invest. 95 (1998) 1735-1740
10. De Vries T.W., de Langen-Wouterse J.J., de Jong-Van, Den Berg L.T., and Duiverman E.J. Hypertrichosis as a side effect of inhaled steroids in children. Pediatr. Pulmonol. 42 (2007) 370-373
11. Dyke H.J., and Montana J.G. The therapeutic potential of PDE4 inhibitors. Expert Opin. Investig. Drugs 8 (1999) 1301-1325
12. 2 agonist and their safety in the treatment of asthma. Allergy Proc. 16 (1995) 235-239
13. Gauvreau G.M., and Evans M.Y. Allergen inhalation challenge: a human model of asthma exacerbation. Contrib. Microbiol. 14 (2007) 21-32
14. Giembycz M.A., and Dent G. Prospects for selective cyclic nucleotide phosphodiesterase inhibitors in the treatment of bronchial asthma. Clin. Exp. Allergy 22 (1992) 337-344
15. Harbinson P.L., MacLeod D., Hawksworth R., O'Toole S., Sullivan P.J., Heath P., Kilfeather S., Page C.P., Costello J., Holgate S.T., and Lee T.H. The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects. Eur. Respir. J. 10 (1997) 1008-1014
16. Howell R.E., Muehsam W.T., and Kinnier W.J. Mechanism for the emetic side effect of xanthine bronchodilators. Life. Sci. 46 (1990) 563-568
17. Ishiwata N., Noguchi K., Kawanishi M., Asakura Y., Hori M., Mitani A., Ito Y., Takahashi K., Nishiyama H., Shudo N., Takahashi S., Takahashi K., Tsuruzoe N., and Nakaike S. NT-702 (parogrelil hydrochloride, NM-702), a novel and potent phosphodiesterase inhibitor, improved the reduced walking distance and the lowered hindlimb plantar surface temperature on rat experimental intermittent claudication model. Life. Sci. 81 (2007) 970-978
18. Ito K., Lim S., Caramori G., Cosio B., Chung K.F., Adcock I.M., and Barnes P.J. A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 8921-8926
19. Jeon Y.H., Heo Y.S., Kim C.M., Hyun Y.L., Lee T.G., Ro S., and Cho J.M. Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development. Cell. Mol. Life. Sci. 62 (2005) 1198-1220
20. Kallstrom T.J. Evidence-based asthma management. Respir. Care 49 (2004) 783-792
21. Lagente V., Moodley I., Perrin S., Mottin G., and Junien J.L. Effects of isozyme-selective phosphodiesterase inhibitors on eosinophil infiltration in the guinea-pig lung. Eur. J. Pharmacol. 225 (1994) 253-256
22. Lagente V., Martin-Chouly C., Boichot E., Martins M.A., and Silva P.M. Selective PDE4 inhibitors as potent anti-inflammatory drugs for the treatment of airway diseases. Mem. Inst. Oswaldo Cruz 100 Suppl 1 (2005) 131-136
23. Leff A.R., Hamann K.J., and Wegner C.D. Inflammation and cell-cell interactions in airway hyperresponsiveness. Am. J. Physiol. 260 (1991) L189-206
24. Lipworth B.J. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 365 (2005) 167-175
25. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily : a new target for the development of specific therapeutic agents. Pharmacol. Ther. 109 (2006) 366-398
26. Matsumori A., Nunokawa Y., and Sasayama S. Pimobendan inhibits the activation of transcription factor NF-kB: a mechanism which explains its inhibition of cytokine production and inducible nitric oxide synthase. Life Sci. 67 (2000) 2513-2519
27. Miura T., and Kimura K. Theophylline-induced convulsions in children with epilepsy. Pediatrics 105 (2000) 920
28. Myou S., Fujimura M., Kamio Y., Hirose T., Kita T., Tachibana H., Ishiura Y., Watanabe K., Hashimoto T., and Nakao S. Bronchodilator effects of intravenous olprinone, a phosphodiesterase 3 inhibitor, with and without aminophylline in asthmatic patients. Br. J. Clin. Pharmacol. 55 (2003) 341-346
29. NHLBI, 2006. National Heart, Lung, and Blood Institute, National Institutes of Health; Global Initiative for Asthma: Global strategy for asthma management and prevention. Workshop Report NIH Publication.
30. O'Byrne P.M., and Inman M.D. Airway hyperresponsiveness. Chest 123 Suppl 3 (2003) 411S-416S
31. Rabe K.F., Tenor H., Dent G., Schudt C., Liebig S., and Magnussen H. Phosphodiesterase isozymes modulating inherent tone in human airways: identification and characterization. Am. J. Physiol. 264 (1993) L458-L464
32. Reinhardt R.R., Chin E., Zhou J., Taira M., Murata T., Manganiello V.C., and Bondy C.A. Distinctive anatomical patterns of gene expression for cGMP-inhibited cyclic nucleotide phosphodiesterases. J. Clin. Invest. 95 (1995) 1528-1538
33. Robicsek S.A., Blanchard D.K., Djeu J.Y., Krzanowski J.J., Szentivanyi A., and Polson J.B. Multiple high-affinity cAMP-phosphodiesterases in human T-lymphocytes. Biochem. Pharmacol. 42 (1991) 869-877
34. Schudt C., Tenor H., and Hatzelmann A. PDE isoenzymes as targets for anti-asthma drugs. Eur. Respir. J. 8 (1995) 1179-1183
35. Shakur Y., Holst L.S., Landstrom T.R., Movsesian M., Degerman E., and Manganiello V. Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family. Prog. Nucleic Acid Res. Mol. Biol. 66 (2001) 241-277
36. Silva P.M., Alves A.C., Serra M.F., Pires A.L., Silva J.P., Barreto E.O., Cordeiro R.S., Jose P.J., Teixeira M.M., Lagente V., and Martins M.A. Modulation of eotaxin formation and eosinophil migration by selective inhibitors of phosphodiesterase type 4 isoenzyme. Br. J. Pharmacol. 134 (2001) 283-294
37. Spina D. Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease. Drugs 63 (2003) 2575-2594
38. Tenor H., Hatzelmann A., Kupferschmidt R., Stanciu L., Djukanović R., Schudt C., Wendel A., Church M.K., and Shute J.K. Cyclic nucleotide phosphodiesterase isoenzyme activities in human alveolar macrophages. Clin. Exp. Allergy 25 (1995) 625-633
39. Torphy T.J. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am. J. Respir. Crit. Care Med. 157 (1993) 351-370
40. Torphy T.J., Undem B.J., Cieslinski L.B., Luttmann M.A., Reeves M.L., and Hay D.W. Identification, characterization and function role of phosphodiesterase isozyme in human airway smooth muscle. J. Pharmacol. Exp. Ther. 265 (1993) 1213-1223
41. Weston M.C., Anderson N., and Peachell P.T. Effects of phosphodiesterase inhibitors on human lung mast cell and basophil function. Br. J. Pharmacol. 121 (1997) 287-295
42. Yao P.L., Tsai M.F., Lin Y.C., Wang C.H., Liao W.Y., Chen J.J., and Yang P.C. Global expression profiling of theophylline response genes in macrophages: evidence of airway anti-inflammatory regulation. Respir. Res. 6 (2005) 89